Niki BioSolutions, Inc. (NASDAQ:NIKI) — Market Cap & Net Worth
Market Cap & Net Worth: Niki BioSolutions, Inc. (NIKI)
Niki BioSolutions, Inc. (NASDAQ:NIKI) has a market capitalization of $2.74 Million ($2.74 Million) as of October 9, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29664 globally and #6036 in its home market, demonstrating a -11.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Niki BioSolutions, Inc.'s stock price $4.32 by its total outstanding shares 634737 (634.74K).
Niki BioSolutions, Inc. Market Cap History: 2026 to 2026
Niki BioSolutions, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $2.74 Million to $2.74 Million (0.00% CAGR). Check Niki BioSolutions, Inc. (NIKI) stock price for real-time trading data and today's change.
Niki BioSolutions, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Niki BioSolutions, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Niki BioSolutions, Inc. (NIKI) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NIKI by Market Capitalization
Companies near Niki BioSolutions, Inc. in the global market cap rankings as of October 9, 2026. See debt-free asset ratio of Niki BioSolutions, Inc. to understand what proportion of total assets are financed by equity.
Key companies related to Niki BioSolutions, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $127.55 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $74.80 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $62.29 Billion USD ( AU$88.04 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $127.55 Billion | $503.25 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $739.57 |
| #450 | CSL Ltd | AU:CSL | $62.29 Billion | AU$181.46 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $197.00 |
Niki BioSolutions, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Niki BioSolutions, Inc.'s market cap moved from $2.74 Million to $ 2.74 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.74 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 9th, 2026 the market cap of Niki BioSolutions, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.74 Million USD |
| MoneyControl | $2.74 Million USD |
| MarketWatch | $2.74 Million USD |
| marketcap.company | $2.74 Million USD |
| Reuters | $2.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Niki BioSolutions, Inc.
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a r… Read more